Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $149.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 21.09% year-over-year to $149.5 million, compared with a TTM value of $149.5 million through Dec 2025, up 21.09%, and an annual FY2025 reading of $149.5 million, up 21.09% over the prior year.
  • Total Non-Current Liabilities was $149.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from $131.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $149.5 million in Q4 2025 and bottomed at -$388.0 million in Q2 2023.
  • Average Total Non-Current Liabilities over 5 years is $58.2 million, with a median of $82.7 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 124.56% in 2024, then increased 21.09% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $31.0 million in 2021, then surged by 97.52% to $61.1 million in 2022, then increased by 29.61% to $79.3 million in 2023, then soared by 55.79% to $123.5 million in 2024, then grew by 21.09% to $149.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CPRX at $149.5 million in Q4 2025, $131.2 million in Q3 2025, and $115.6 million in Q2 2025.